Allogene <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Potential Risk as Cellectis Hit with Patent Infringement Lawsuit Over TALEN Gene-Editing Technology
Allogene Therapeutics Inc. disclosed that Factor Bioscience Inc. has filed a complaint in the United States District Court for the District of Delaware against Cellectis S.A. and its affiliate, alleging infringement of three U.S. patents related to gene-editing techniques. The complaint claims that Cellectis's TALEN-based gene-editing technology, which Allogene licenses for use in developing its allogeneic CAR T cell product candidates, infringes Factor's patented mRNA TALEN technology. AstraZeneca and certain affiliates are also named as defendants in the lawsuit for direct infringement. While Allogene is not currently a party to the litigation, it relies on the disputed technology for key products and could face future claims as a commercial user. Cellectis has informed Allogene of its intent to vigorously defend against Factor's allegations. The situation poses intellectual property risks for Allogene, as outlined in its recent SEC filings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-044828), on October 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。